FDA Accepts Supplement for MYDAYIS by Takeda
The FDA has accepted a supplemental application for MYDAYIS, a medication for ADHD, from Takeda Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for MYDAYIS with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.